Molecular Imaging: Page 79

MITA takes aim at CMS proposal to limit Alzheimer's drug coverage

By AuntMinnie.com staff writers

The Medical Imaging & Technology Alliance (MITA) is speaking out against changes proposed by the U.S. Centers for Medicare & Medicaid Services (CMS) to restrict payments related to new drugs to treat Alzheimer's disease.

January 20, 2022

Claritas iPET software given FDA clearance

By AuntMinnie.com staff writers

Claritas HealthTech recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Claritas iPET image processing software.

January 20, 2022

FAPI-PET may improve diagnosis of gastric cancer

By Will Morton

Hybrid PET/MR imaging with an experimental gallium-68-labeled fibroblast activation protein inhibitor (FAPI) radiotracer outperforms standard molecular imaging for diagnosing gastric cancer, according to a study published in the January issue of the Journal of Nuclear Medicine.

January 18, 2022

Could imaging payments for Aduhelm patients bust Medicare?

By Will Morton

Overlooking imaging costs related to the controversial Alzheimer's disease drug aducanumab (Aduhelm) prior to its approval was a mistake that could ultimately threaten Medicare's solvency, according to an analysis published January 14 in JAMA Health Forum.

January 13, 2022

SNMMI warns of omicron's impact on PET/CT scans

By Will Morton

The COVID-19 omicron variant appears to cause an unusual imaging pattern on FDG-PET/CT scans in cancer patients, according to a statement released January 14 by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) COVID-19 Task Force.

January 13, 2022

Radiohybrid tracer superior to CT in prostate cancer imaging

By Will Morton

An experimental radiohybrid PET tracer is more effective than CT for identifying tumors prior to surgery in patients with advanced prostate cancer, according to a study published January 6 in the Journal of Nuclear Medicine.

January 12, 2022

CMS to limit coverage of new drugs for Alzheimer's disease

By Will Morton

The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed a national coverage determination that would limit coverage for drugs like aducanumab only to people enrolled in qualifying clinical trials.

January 11, 2022

Clario, XingImaging expand PET partnership

By AuntMinnie.com staff writers

Clinical trial management services firm Clario, formerly ERT and Bioclinca, has expanded its partnership with Chinese radiopharmaceutical manufacturer and PET contrast research organization XingImaging.

January 10, 2022

AuntMinnie.com Molecular Imaging Insider

By Will Morton

January 10, 2022

Ga-68 radiotracer outperforms F-18 FDG in lung cancer staging

By Will Morton

PET/CT imaging with an experimental gallium-68-based (Ga-68) radiotracer that binds to overactive fibroblast cells in tumors outperforms standard methods for detecting the spread of lung cancer, according to a study published January 4 in Radiology.

January 10, 2022

Eckert & Ziegler inks ytterbium-176 supply deal

By AuntMinnie.com staff writers

Eckert & Ziegler Radiopharma, the production arm of isotope technology firm Eckert & Ziegler, has inked a supply deal with Atom Mines for the radiopharmaceutical ytterbium-176.

January 9, 2022

Best Cyclotron Systems merges with Best ABT

By AuntMinnie.com staff writers

Best ABT Molecular Imaging and Best Cyclotron Systems, both part of TeamBest Global Companies, recently merged into one entity.

January 6, 2022

Previous Page

Page 79 of 614

Next Page